I think NAN may drift here a bit without any news for a while. For me I am confident the NHS are coming on board but the revenue will take a while to flow and market is much smaller than the US. The US market seems to be going well.
2 catalysts that will see a re rating is signs of inroads into a non anglo market ie Japan and the announcement of their new product even though that may take a while to get through the FDA etc.
I have no idea how receptive the Japanese market will be the trophon. At first glance I would have thought the concept would be very attractive but there may be other barriers such as funding, bias against non japanese tech etc.
NAN Price at posting:
$2.56 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)